Kyowa Hakko Kirin Enters New Development and Commercialisation Agreements with AstraZeneca for All Benralizumab Indications beyond COPD and Asthma in Asia Inclusive of Japan
(WorldNews Japan)

March 25, 2019 (161KB) Tokyo, Japan, March 25, 2019 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Masashi Miyamoto, `Kyowa Hakko Kirin`) announces that the company has entered new agreements with AstraZeneca granting AstraZeneca exclusive rights to benralizumab (brand name `Fasenra`) for all additional indications in Asia inclusive of Japan. Under previous agreements, AstraZeneca currently has the rights to benralizumab in the countries and regions for...